None of the content of the manuscript contains any information that could be patentable or claimed as intellectual property of the contributors or their respective companies
doi: 10.1016/j.neuroscience.2016.01.070
In a phase 2 clinical trial for obesity, 26 weeks of efinopegdutide (doses 5 to 10mg) resulted in up to 11.8% WL in people with obesity (without diabetes) compared to 7.5% WL with liraglutide 3 mg and 1.8% WL with placebo [77, 78]
Neurologic manifestations are caused by progressive demyelination and can include peripheral neuropathy, areflexia, and the loss of proprioception and vibratory sense
Herasimenka, Y., Benincasa, M., Mattiuzzo, M., Cescutti, P., Gennaro, R., and Rizzo, R., Peptides , 2005, vol